Australia markets open in 8 hours 24 minutes
  • ALL ORDS

    7,051.00
    +36.00 (+0.51%)
     
  • AUD/USD

    0.7741
    +0.0046 (+0.60%)
     
  • ASX 200

    6,770.40
    +27.80 (+0.41%)
     
  • OIL

    53.65
    +0.67 (+1.26%)
     
  • GOLD

    1,858.60
    +18.40 (+1.00%)
     
  • BTC-AUD

    45,318.11
    +455.70 (+1.02%)
     
  • CMC Crypto 200

    692.00
    -8.61 (-1.23%)
     

COVAXX gets supply deals worth $2.8 bln for potential COVID-19 vaccine

·1-min read

Nov 25 (Reuters) - COVAXX, a unit of United Biomedical Inc, said on Thursday it has received purchase commitments totaling $2.8 billion to deliver more than 140 million doses of its potential COVID-19 vaccine to developing countries, including Brazil, Peru and Ecuador.

The multitope peptide-based vaccine is currently in early-stage trials in Taiwan, lagging some of the frontrunners in the race to develop a safe and effective vaccine.

The U.S.-based company signed an agreement in September with Brazilian lab and hospital group DASA S.A. to conduct mid-to-late stage trials in Brazil for the vaccine.

COVAXX estimates it can produce 100 million doses in first half of next year and 1 billion by end of 2021.

Last month, the company signed a logistics partnership with Maersk for transportation and supply chain services that will be needed to deliver the vaccine around the world. (Reporting by Mrinalika Roy in Bengaluru; Editing by Arun Koyyur)